Story
regulates · 1
Weight-loss drugs are a legitimate choice, not a sign of failure, but the full account matters: in the STEP-1 trial, semaglutide 2.4 mg once a week for 68 weeks produced an average weight loss of 14.9%, against 2.4% on placebo, and most of the weight tends to come back after stopping. This is long-term treatment for a chronic condition, not a single course.
contrast · 2
Body mass index (BMI) cannot tell muscle from fat, so many people turn to body-fat percentage instead; but compared with the reference method, the error range of a body-fat scale reading typically spans 15–20 percentage points. Neither number alone answers whether you carry too much fat; read them together with waist size and other signs.
Surgery and weight-loss drugs are not a sign that willpower failed; they are legitimate options once the criteria are met. Under the 2022 ASMBS/IFSO standard, metabolic and bariatric surgery is recommended at a BMI of 35 or more and should be considered at 30–34.9 with metabolic disease; for Asian people the thresholds are lower, and surgery should be offered from a BMI of 27.5.